Curis (CRIS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Soumit Roy from JonesTrading maintained a Buy rating on the stock and has a $12.00 price target.
Soumit Roy has given his Buy rating due to a combination of factors related to Curis’s ongoing clinical developments and strategic plans. The company is making significant progress in its PCNSL study, with a target to enroll 30-40 patients over the next 12-18 months, and has the support of 37 clinical sites for enrollment. The potential for accelerated approval of the emavusertib and ibrutinib combination therapy, based on promising feedback from the FDA and EU CHMP, further strengthens the outlook for Curis.
Additionally, Curis is advancing its AML program by focusing on the safety studies of a triplet combination therapy. The completion of the 7-day safety cohort without any concerns and the ongoing evaluation of a 14-day dosing regimen indicate a positive trajectory. The company’s broader strategy to expand into all lymphoma indications with an approved BTK inhibitor also adds to the optimistic view. These strategic initiatives and clinical advancements underpin Soumit Roy’s Buy rating for Curis.